Abstract _ Full Text (HTML) _ Full Text (PDF)

Case Report

Cancer Research Frontiers. 2014 Feb; 1(1): 99-103. doi: 10.17980/2015.99

Frontline Clofarabine and Cytarabine combination for plasmocytoid blastic dendritic cell neoplasm

Rudy Birsen1,2, Valerie Bardet2,3, Tali-Anne Szwebel2,4, Benedicte Deau1,2, Elisabeth Aslangul2,4, Sophie Galimard2,4, Stephanie Mathis2,3, Nicolas Chapuis2,3, Didier Bouscary1,2 and Jerome Tamburini1,2*

 

1Hematology Department, Cochin Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris;
2Paris 5 University, Paris;
3Hematology Laboratory, Cochin Hospital, AP-HP, Paris;
4Internal Medicine Department, Cochin Hospital (AP-HP), Paris, France.

*Corresponding author: Email: jerome.tamburini@cch.aphp.fr

Citation: Birsen R, et al. Frontline Clofarabine and Cytarabine combination for plasmocytoid blastic dendritic cell neoplasm. Cancer Research Frontiers. 2015 Feb; 1(1): 99-103. doi: 10.17980/2015.99

Copyright: @ 2015 Birsen R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors declare that they have no competing interests.

Received: Oct 23, 2014; Revised: Dec 2, 2014; Accepted: Jan 9, 2015.

 

Abstract

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematological cancer usually involving skin and/or bone marrow. Recent molecular evidence suggests that BPDCN originates from the myeloid lineage. Short-term responses to conventional treatments underline the need for new therapies in this disease. We present the case of a 55-year-old woman with therapy-related leukemic-phase BPDCN who experienced a six month remission following clofarabine and cytarabine combination therapy. Intensive anthracyclin-based regimen and stem-cell transplant (SCT) were excluded due to pre-existing severe cardiac dysfunction. Relapse occurred after six month of complete remission and the patient died from thrombocytopenia-induced intracranial bleeding. For elderly or young BPDCN patients not eligible for intensive regimen or in relapsed/refractory disease, clofarabine-based therapy appears as an option. 

Keywords : Clofarabine, Cytarabine, blastic plasmacytoid dendritic cell neoplasm.

 

 

 

 

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann